ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

Arrillaga-Romany, I., Lassman, A., McGovern, S. L., Mueller, S., Nabors, B., van den Bent, M., Vogelbaum, M. A., Allen, J. E., Melemed, A. S., Tarapore, R. S., Wen, P. Y., & Cloughesy, T. (2024). ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-Oncology, 26(Supplement_2), S173–S181. https://doi.org/10.1093/neuonc/noae031
Authors:
Isabel Arrillaga-Romany
Andrew Lassman
Susan L McGovern
Sabine Mueller
Burt Nabors
Martin van den Bent
Michael A Vogelbaum
Joshua E Allen
Allen S Melemed
Rohinton S Tarapore
Patrick Y Wen
Timothy Cloughesy
Affiliated Authors:
Andrew Lassman
Columbia Affiliation:
Subjects:
Glioma (MeSH)
Brain Neoplasms (MeSH)
Mutation (MeSH)
Author Keywords:
h3 k27m
onc201
phase 3
diffuse glioma
dordaviprone
elink
Publication Type:
Article
Unique ID:
10.1093/neuonc/noae031
PMID:
38445964
DOI:
10.1093/neuonc/noae031
Journal:
Neuro-Oncology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: